Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Russian drug manufacturers are eliminating global players from the domestic insulin market, as their sales are steadily ...

Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai ...

Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with ...

Compounding pharmacies have emerged as a crucial player in the evolving landscape of personalized medicine, offering ...

A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and ...

“We are excited to collaborate with Scienture to enhance its commercial effectiveness,” said Paul Mignon, President, Deployment Solutions, Syneos Health. “Our team is committed to delivering tailored ...

Alumis (NASDAQ:ALMS) stock surges 14% after the company reached a licensing deal with Kaken (KKPCF) for its skin disorder ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...